Abstract
Type I hyperprolinemia (HPI) is an autosomal recessive disorder associated with cognitive and psychiatric troubles, caused by alterations of the Proline Dehydrogenase gene (PRODH) at 22q11. HPI results from PRODH deletion and/or missense mutations reducing proline oxidase (POX) activity. The goals of this study were first to measure in controls the frequency of PRODH variations described in HPI patients, second to assess the functional effect of PRODH mutations on POX activity and finally to establish genotype/enzymatic activity correlations in a new series of HPI patients. 8/14 variants occurred at polymorphic frequency in 114 controls. POX activity was determined for 6 novel mutations and 2 haplotypes. The c.1331G>A, p.G444D allele has a drastic effect whereas the c.23C>T, p.P8L allele and the c.[56C>A; 172G>A], p.[Q19P; A58T] haplotype result in a moderate decrease in activity.
Among the 19 HPI patients, 10 had a predicted residual activity <50%. 8 out of 9 subjects with a predicted residual activity ≥50% bore at least one c.824C>A, p.T275N allele, which has no detrimental effect on activity but whose frequency in controls is only 3%. Our results suggest that PRODH mutations lead to a decreased POX activity or affect other biological parameters causing hyperprolinemia. 
Introduction
Type I hyperprolinemia (MIM# 239500) is characterized by an increase in plasma proline level in absence of urinary pyrroline-5-carboxylate (P5C) (typical of type II hyperprolinemia).
It was initially described in 1962 as a nephropathy associated with cerebral dysfunction [Efron, 1965; Schafer et al., 1962] . The association with renal disease was fortuitous and was due to a recruitment bias since patients with nephropathy were preferentially screened by amino acid chromatography at this time. As a result of the analysis of new families with HPI ten years later, it was considered that hyperprolinemia was a benign condition without mental retardation or renal dysfunction [Mollica et al., 1976] . The gene associated with this condition, named PRODH (MIM# 606810), was mapped in 1997 on 22q11 [Campbell et al., 1997] and encodes for proline oxidase (POX), the first enzyme involved in proline catabolism. Its expression is limited to liver, brain and kidney. In 1999, a mouse model deficient for POX was described. These mice present behavioral problems, especially a sensory motor gating impairment, which is an endophenotype of schizophrenia [Gogos et al., 1999] . A few years later, [Humbertclaude et al., 2001 ]described a case with severe neurologic impairment and raised the question whether HPI really was a benign trait in humans, which opened up again the discussion.
In 2003, we described [Jacquet et al., 2003 ] a recurrent 350kb deletion encompassing the PRODH and DGCR6 (MIM# 601279) genes, mediated by low copy repeats surrounding this region, which was subsequently found to be present in 1/250 individuals in the general population [Guilmatre et al., 2009; Ohtsuki et al., 2004] . Numerous missense mutations in the PRODH gene have also been described, most of them appearing recurrently because of a gene conversion between PRODH and a non-processed pseudogene located 1.4 Mb telomeric on chromosome 22 [Liu et al., 2002] . A functional characterization of POX enzymatic activity 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   5 was established demonstrating that some of these mutations had a severe impact (> 70% reduction) on its activity whereas others had a mild or moderate effect [Bender et al., 2005] .
Further genetic studies in 3 patients with mental retardation, epilepsy and very high plasma proline level allowed us to establish that the severe form of HPI was a recessive disorder resulting from homozygous PRODH/DGCR6 deletion or mutations with a drastic effect on enzymatic activity [Jacquet et al., 2003] . In accordance with the mouse model phenotype, hyperprolinemia was then shown to be a risk factor for schizoaffective disorder [Jacquet et al., 2005] . The link between hyperprolinemia and cognitive or psychiatric troubles was further strengthened by the study of patients with velo cardio facial syndrome (VCFS) that results from a 1.5-3Mb deletion on chromosome 22q11. Although all these patients are hemizygous for the PRODH gene, only 30-50% have elevated plasma proline level [Goodman et al., 2000; Raux et al., 2007] , while 50% have mental retardation and 30% psychosis [Murphy et al., 1999] . We have shown that in VCFS increased plasma proline level (in association with the COMT (MIM# 116790) genotype) was a risk factor for psychosis and that prolinemia was inversely correlated to IQ [Raux et al., 2007] . Based on the functional predictions, this study also showed that a reduction of at least 50% of the enzymatic activity was required to produce mild to moderate hyperprolinemia while severe hyperprolinemia was generally associated with a near complete loss of enzymatic activity. In addition to these observations, PRODH/DGCR6 deletion and mild hyperprolinemia were recently found at a high frequency in autistic subjects [Guilmatre et al., 2009] .
Despite this large body of data, several points remain to be clarified. In particular, correlations between PRODH genotype and various levels of hyperprolinemia, ranging from mild to severe, remain poorly understood. In the present report, three issues were examined: first we measured in controls the allelic frequency of PRODH variations found in HPI patients, second
we assessed the functional effect of previously uncharacterized mutations or haplotypes on 
Material and methods
This study was approved by the Ethics Committee of Rouen University Hospital.
Controls
To establish the allelic frequency of PRODH (NM_016335) variants, we genotyped 114 healthy caucasian subjects originating from France (46 men, 68 females) previously included in a study aimed to establish the normal values of plasma proline in the adult population [Jacquet et al., 2005] . Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.
Patients with HPI
Blood samples from patients with HPI were sent to our laboratory from centers expert in the diagnosis of Autism or mental retardation in order to analyze the PRODH gene. All patients were examined by experienced clinicians and psychiatric diagnoses were made according to DSM IV criteria. Biological investigations included MRI imaging, karyotype, Fragile X testing and amino-acid chromatography. Plasma proline levels were determined by ion exchange chromatography after overnight fasting. After informed consent was obtained, DNA was extracted from peripheral lymphocytes. Patients as well as their parents were genotyped in order to obtain the phase of the mutations.
PRODH sequencing and QMPSF
PRODH exons were sequenced using PCR conditions and primers previously described [Jacquet et al., 2005; Raux et al., 2007] . In some subjects in which PRODH exon 7 could not be amplified , due to indels in both flanking introns, the presence of the c.824C>A, p.T275N variation was assessed using the forward primer 5'TGCAGTTCTCAGAGGTGCTG 3' in combination with the previously described reverse primer.
PRODH deletions were characterized by quantitative multiplex analysis of short fluorescent fragments (QMPSF), as previously described [Jacquet et al., 2002] .
Array CGH
DNA samples were analyzed using Human High-Resolution Discovery Microarray Kit 4x180K (Agilent Technologies, Santa Clara, California, USA), using standard recommended protocols. Non commercial genomic DNA pool of 10 control individuals was used as reference. Hybridization results were extracted with Feature extraction software and analyzed using Agilent's DNA-analytics software. The data were processed using ADM-2 algorithm, with the threshold set at 6.0 SD.
Functional assay for POX activity
We purchased restriction enzymes and buffers from New England Biolabs: Pfu-Turbo DNA polymerase from Stratagene and chemicals from Sigma.
14 C-proline was obtained from New England Nuclear and purified prior to use by ion-exchange chromatography on Dowex AG 50w-8x hydrogen form (BioRad) [Phang et al., 2001] . To assay green fluorescent protein (GFP) fluorescence, we used a Zeiss LSM 510 Meta confocal laser-scanning microscope.
Functional test was realized as previously described [Bender et al., 2005] . Briefly, the PRODH ORF divided into three fragments previously cloned in the pBluescript KS vector (Stratagene) was used to perform the mutagenesis and the wild-type PRODH cDNA previously cloned into pTracer (Invitrogen) was used for expression analysis. We mutagenized the ClaI/BstEII-modified PRODH cDNA in pBluescript KS by PCR using the QuikChange Mutagenesis Kit (Stratagene). Dependent on the position of the desired mutation, we subcloned either the mutagenized KpnI/ClaI or mutagenized ClaI/BstEII with the Pierce BCA protein assay (Pierce). POX-specific activity (nmol/prod/mg/hr) was assayed radioisotopically, as described elsewhere [Phang et al., 1975] . To account for variation in transfection efficiency, we expressed the data as a percentage of wild type (specific activity of mutant allele/transfection efficiency)/( specific activity of wild-type allele/transfection efficiency). For alleles with severe reduction in POX activity, we repeated the assay with the addition of 1 mM FAD. All samples were assayed in triplicate in independent transient transfection experiments.
Ex vivo splicing assay using a splicing reporter minigene
This assay was used to test the effect of the p.T275N variant in PRODH exon 7 splicing. This assay was realized in both Hela and ShSY5Y cells using the same protocol [Tournier et al., 2008] , with DMRIE-C (Invitrogen) as the transfection reagent for the SH-SY5Y cells. Primer sequences are available upon request. The genotyping of 114 controls without psychiatric or neurological disorders (four of them having plasma proline level above the upper threshold, range 389-482 µmol/l) allowed us to determine in a control population the frequency of missense mutations that were present in HPI patients [Raux et al., 2007] (and this study) (Table 1) 
Results

Frequency of PRODH variations in controls
Functional consequences of PRODH missense mutations
In addition to data already reported, that are summarized in Supp In this series of patients, abnormal plasma proline levels ranged from 1667 to 327 µmol/l with, for several subjects, considerable variation between two measures obtained at different time (Table 2b ). Based on the results of functional assay, four subjects had a genotype predicted to result in a drastic loss of enzymatic activity. In accordance with these predictions, they all present with severe hyperprolinemia. Overall, only 10/19 patients had a predicted residual activity <50% which, according to our working hypothesis [Raux et al., 2007] , is required to produce hyperprolinemia. Strikingly, 8 out of 9 subjects with a predicted residual enzymatic activity ≥50% bore at least one p.T275N allele, which has no effect on enzymatic activity but whose frequency in the control population is only 3%. Using an ex vivo splicing assay to further analyse the effect of this variant, we observed no effect on the splicing pattern of PRODH exon 7 (data not shown).
Discussion
All patients included in this report present cognitive impairment and/or behavioral problems.
Epilepsy was also frequent. It should however be stressed that this study was not designed to is associated with psychiatric and neurologic disabilities, our data may just reflect a recruitment bias since subjects presenting such conditions are more likely to be screened for inborn error of amino acid metabolism than normal subjects.
Nonspecific dysmorphic features were present in a subset of patients raising the question of a putative link between HPI and syndromic MR. In these patients, array CGH analysis failed to document the co-occurrence of another genetic abnormality that can explain these physical features. Thus, it remains unclear whether dysmorphism may be a component of the HPI syndrome or whether another as yet undetected genetic defect is present in this subset of patients.
Concerning the relationship between plasma proline and the predicted POX activity, a rather poor correlation was observed. However, as previously noted [Bender et al., 2005 ] our functional assay circumvent any effect these mutations might have on RNA splicing or protein stability. It is thus conceivable that several variations may be wrongly classified as benign on the basis of this sole test. In a previous report concerning VCFS patients we had already noted the unexplained enrichment of the c.1292G>A, p.R431H mutation in patients with high proline levels [Raux et al., 2007] . In the present report, the increased frequency of the functionally neutral p.T275N mutation in HPI patients is noteworthy, pointing out that it is indeed a probable pathologic variant. Since this variation does not modify the splicing pattern of exon 7, its biological effect remains elusive and it is most likely in linkage disequilibrium with another functional variant. Indeed, DNA variations in the regulatory regions or in introns of PRODH may influence transcription or splicing of the gene. A polymorphism located in the 5' region of PRODH and resulting in a 1.5-fold increase in promoter activity has been described [Hoogendoorn et al., 2004] . However, genotyping this polymorphism in our As previously noted, plasma proline is subject to fluctuations over time in most patients, thus requiring, as a rule, repeated determinations. However, several patients bearing a potentially deleterious genotype had only mild hyperprolinemia on repeated measures. Since it seems unlikely that such a slight increase in proline level is sufficient to produce a detrimental effect, this result questions the value of plasma proline level determination as an estimate of CNS proline value. Because peripheral proline cannot gain access to the central nervous system (CNS) across the blood-brain barrier [Hawkins et al., 2006] , blood and brain proline form two largely independent pools. Brain proline, the concentration of which in the cerebro spinal fluid (CSF) is low (4.2 µmol/l), is not subject to nutritional fluctuations. Its level depends on local synthesis from ornithine and glutamate and from degradation of collagen of the extra cellular matrix. In severe HPI [Efron, 1965; Humbertclaude et al., 2001 ] as well as in PRODH -/-mice [Gogos et al., 1999] , CNS concentration of proline is elevated.
Unfortunately, CSF data are not available for our patients.
Another point to be kept in mind when interpreting slight increases in plasma proline is that normative values of plasma proline are lower in children as compared with adults.
Accordingly, in mice PRODH transcripts are expressed at higher level in the young brain as compared with the mature brain [Maynard et al., 2003] . Physiologically, the fine tuning of PRODH expression facilitates proline catabolism during periods in which most refinement and stabilization of synaptic connections occur. Therefore, it can be hypothesized that any genetic defect causing even a modest increase in proline levels during critical periods of development may have a dramatic effect on CNS functioning. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1. The thin vertical lines indicate standard deviation.
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